Composite Probes and Use Thereof in Super Resolution Microscopy

The technology is in the field of fluorescence microscopy. More specifically, the invention describes and claims the composite probes for super resolution optical techniques using super resolution via transiently activated quenchers (STAQ). The composite probes include a donor moiety and an acceptor moiety joined by a linker. The acceptor moiety, when excited by incident radiation, is excited to a state which, for example, absorbs in the donor emission region, such that the acceptor moiety in its excited state quenches at least a portion of the donor moiety emission.

Highly Potent and Selective Deubiquitinating Enzyme Inhibitor

Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from a narrow therapeutic index and acquired resistance. A promising alternative to proteasome inhibition has been to target the enzymes upstream of proteasome-mediated protein degradation, i.e.

Potency Assay for Membrane Transporter Protein-based Drugs Acting on Antioxidant, Redox, and Apoptosis Response Pathways

This technology includes a method of analyzing the potency of membrane transporter protein-based drugs acting on intracellular antioxidant and redox response pathways (and associated apoptosis pathways), wherein the drug delivery and activity is lipid associated. The present invention is a cell-based bioassay for measuring the bioactivity of drug substance and formulated drug product by determining the drug's dose-dependent inhibitory effects on 4 hydroxynonenal (4-HNE)-induced antioxidant response element (ARE) activity.

Optimized Nucleotide Sequence for RLIP-76 - A Membrane-associated Lipid Peroxidation Transporter for Radiation Poisoning

This technology includes a codon optimized expression vector for the high expression and production of RLIP-76 which can be used to provide protection from radiation. RLIP-76 is a multifunctional membrane protein that transports glutathione conjugates of electrophilic compounds outside the cell. The sequence was generated with codon bias alterations, reduction of secondary structure, lowering of GC content, and removal of cryptic elements that could affect expression in E.coli.

Formulation of a Modified Stable FGF-1 (TTHX1114) to Accelerate Corneal Endothelium Regeneration

This technology includes the use of a novel formulation for an engineered version of Fibroblast Growth Factor 1 (FGF1), TTHX1114, that can be used to accelerate regeneration of the corneal endothelium after surgical lesions. FGFs are well-established regulators of migration and proliferation of corneal endothelial cells (CECs).

Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer Treatment

This technology includes the use of pyridines for anticancer treatment. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer cells. Thioredoxin Reductase 1 (Trxr1) is an important selenoprotein in the thioredoxin antioxidative system which has been implicated as a potential anti-cancer target.

Immunotherapy Combination Treatment Containing both TLR4 and TLR2/6 Agonists, a Checkpoint Inhibitor, and a STING agonist.

Melanoma is an aggressive form of skin cancer that commonly becomes metastatic, spreading to nearby tissue or other parts of the body, including distant skin or subcutaneous sites such as the lungs, liver, brain, or bone. Metastatic melanoma is very drug resistant and difficult to treat, and therefore, the prognosis for these patients is poor. There is a need for effective therapies for aggressive melanoma and other drug-resistant solid cancers. 

Subscribe to Leidos